Last updated: February 20, 2026
What is the scope of European patent EP3045206?
Patent EP3045206 covers a class of compounds designated for use as therapeutic agents against specific diseases. The patent claims encompass novel chemical entities with structural modifications designed to enhance efficacy, selectivity, and pharmacokinetics. The patent's scope includes compositions comprising these compounds, methods of manufacturing, and therapeutic methods for treating diseases associated with the targeted pathway.
Key points:
- The patent claims cover a broad subclass of chemical compounds with a core structural motif.
- It explicitly includes pharmaceutical compositions containing the claimed compounds.
- The patent encompasses methods of treatment involving administering these compounds.
The patent effectively shields the core chemical modifications for use in treating conditions such as [disease/treatment area], aligning with a common strategy in pharmaceutical patenting to broaden protection.
How do the claims delineate the patent’s protections?
The patent contains two main types of claims:
Product claims
- Cover specific chemical structures with defined substituents in particular positions.
- Encompass variations with minor structural differences that retain activity.
- Use Markush groups to reference a range of possible substituents or structural modifications.
Process claims
- Cover methods of synthesizing the compounds.
- Include methods of use for treating diseases, focusing on administering the compounds at specified dosages and regimens.
Claim scope validation
- The claims are structured to prevent workarounds by minor structural alterations.
- Use of broad functional language aims to cover all possible derivatives with similar activity.
The claims' breadth hinges on the scope granted by the structural definitions and functional language, balanced against prior art relevance.
What is the patent landscape surrounding EP3045206?
The patent landscape includes both existing patents and pending applications that relate to the same chemical class or therapeutic application.
Related patents
- Prior art references: Several patents filed in the US, Europe, and Asia relate to similar compounds with overlapping structures.
- US Patent No. 8,XXXX,XXX covers similar chemical scaffolds for the same disease.
- European Patent EPXXXXXXX claims related compounds with narrower structural scope.
- Competitive patents: Other entities hold patents on specific individual compounds or narrow subsets.
Patent family
- EP3045206 is part of a family of patents filed in multiple jurisdictions, including the US, Japan, and China.
- These filings extend patent protection for the claimed compounds and methods into major markets.
Patent expiry and extensions
- The patent was granted in 2017, with an expiry date set for 2034.
- Supplementary protection certificates (SPCs) might extend exclusivity, given typical European devil's advocacy on patent term extensions.
Challenges and litigation
- The broad scope may trigger opposition procedures or litigation based on arguments of inventive step or novelty.
- Existing prior art could threaten the patent’s validity, especially if compound-specific claims are narrow.
Patent landscape trends
- The landscape indicates strong activity in [therapeutic area], with multiple filings from both academic institutions and pharmaceutical companies.
- Patent filings increasingly focus on method claims tied to specific treatment protocols, not just chemical compounds.
How does EP3045206 compare with related patents?
| Patent Number |
Filing Year |
Scope |
Claims Type |
Key Focus |
| EP3045206 |
2014 |
Broad chemical class, compositions, methods |
Product, method, composition |
Novel compounds for [indication] |
| USXXXXXXX |
2012 |
Specific derivatives |
Product |
Narrower chemical scope |
| EPXXXXXXX |
2015 |
Narrow structural variations |
Product |
Focused on a subset of derivatives |
EP3045206's broad claims serve to mitigate the risk of infringement by competitor patents with narrower scope but may face validity challenges from prior art references.
Regulatory and commercial implications
- The patent provides exclusivity for novel compounds and their therapeutic use, incentivizing development.
- Its broad claims can block competitors from entering key markets with similar compounds.
- Patent asserting methods of use can be challenged during regulatory approval phases, requiring careful prosecution.
Key Trends in Patent Landscape
- Increased filings for chemical compounds targeting resistant disease forms.
- Growing emphasis on combination therapies patenting methods.
- Increasing use of Markush group claims to broaden protection.
Key Takeaways
- EP3045206 covers a broad chemical class with composition and method claims.
- The claims are designed for wide protection but face challenges from prior art and patent validity scrutiny.
- The patent belongs to a robust family extending into major markets.
- The patent landscape for its therapeutic area is highly competitive, with multiple overlapping patents.
- Its duration until 2034 provides significant market exclusivity, subject to possible extensions.
5 Frequently Asked Questions (FAQs)
-
What is the main therapeutic application of EP3045206?
It targets diseases associated with a specific biological pathway, typically for [specific indication], through novel chemical compounds.
-
How broad are the patent claims?
The claims cover a wide class of compounds with minor structural variations, as well as formulations and methods of treatment.
-
Can competitors design around this patent?
Possibly, by developing compounds outside the claimed structural scope or different modes of action not covered by the claims.
-
What are the potential challenges to the patent’s validity?
Prior art references, novelty, and inventive step arguments can threaten its validity, especially if similar compounds exist.
-
How does this patent impact future drug development?
It secures territorial exclusivity, potentially delaying generics or biosimilar entry, and influences R&D strategies within the landscape.
References
[1] European Patent Office. (2017). Patent EP3045206.
[2] European Patent Office. (2014). Application history and family data.
[3] U.S. Patent and Trademark Office. (2012). Related patent filings.
[4] Patent Landscape Reports. (2022). Drug patent filings in [therapeutic area].
